Oral BMS-354825 rescues Gleevec-resistant CML

被引：0
|
作者：
不详
机构：
来源：
CANCER BIOLOGY & THERAPY | 2004年 / 3卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：700 / 700
页数：1
相关论文
共 50 条
  • [31] Dasatinib (BMS-354825) inhibits migration and invasion of human melanoma cells and is a promising therapeutic agent for metastatic melanoma
    Buettner, Ralf R.
    Nam, Sangkil
    Lee, Frank
    Jove, Richard
    CANCER RESEARCH, 2006, 66 (08)
  • [32] Dasatinib (BMS-354825): A multi-targeted kinase inhibitor with activity against multiple myeloma.
    Deng, QW
    Mitsiades, N
    Negri, J
    Wen, ZQ
    Rooney, M
    Hideshima, T
    Chauhan, D
    Munshi, NC
    Richardson, PG
    Lee, FY
    Anderson, KC
    Mitsiades, CS
    BLOOD, 2005, 106 (11) : 451A - 451A
  • [33] Pediatric preclinical testing program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825)
    Smith, M. A.
    Maris, J. M.
    Keir, S. T.
    Friedman, H. S.
    Lock, R. B.
    Kolb, E. A.
    Keshelava, N.
    Reynolds, C. P.
    Morton, C.
    Houghton, P. J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 101 - 101
  • [34] BMS-214662 targets quiescent chronic myeloid leukaemia stem cells and enhances the activity of both imatinib and dasatinib (BMS-354825).
    Copland, M
    Hamilton, A
    Allan, EK
    Brunton, V
    Holyoake, TL
    BLOOD, 2005, 106 (11) : 204A - 205A
  • [35] Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
    Chang, Alex Y.
    Wang, Miao
    BMC CANCER, 2013, 13
  • [36] Activity of AMN107 in Gleevec-resistant leukemia - AMN107 has potent activity in leukemia resistant to Gleevec
    不详
    CANCER BIOLOGY & THERAPY, 2006, 5 (01) : 8 - 8
  • [37] BMS-354825 (BMS) inhibits the kinase activity of mutant KIT proteins associated with seminomas (S) and has synergistic effects with cisplatin (CDDP).
    Schittenhelm, MM
    Shiraga, SH
    Griffith, DJ
    Schroeder, AJ
    Lee, FY
    Bokemeyer, C
    Heinrich, MC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 424S - 424S
  • [38] Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
    Kamath, Amrita V.
    Wang, Jian
    Lee, Francis Y.
    Marathe, Punit H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) : 365 - 376
  • [39] The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
    Tokarski, John S.
    Newitt, John A.
    Chang, Chieh Ying J.
    Cheng, Janet D.
    Wittekind, Michael
    Kiefer, Susan E.
    Kish, Kevin
    Lee, Francis Y. F.
    Borzillerri, Robert
    Lombardo, Louis J.
    Xie, Dianlin
    Zhang, Yaqun
    Klei, Herbert E.
    CANCER RESEARCH, 2006, 66 (11) : 5790 - 5797
  • [40] Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC).
    Jabbour, E
    Cortes, J
    Talpaz, M
    Jones, D
    O'Brien, S
    Nicaise, C
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 318A - 318A
12345